MarketPulse

REDEFINE 4

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Novo Nordisk Faces Securities Fraud Investigation After CagriSema Trial Failure

Portnoy Law Firm investigates Novo Nordisk for possible securities fraud after CagriSema obesity drug failed trial, triggering 16.43% stock decline.
LLYNVOsecurities fraudclass action
BenzingaBenzinga··Vandana Singh

Novo Nordisk's CagriSema Falls Short in Weight-Loss Trial Against Lilly's Tirzepatide

Novo Nordisk's CagriSema underperformed Eli Lilly's tirzepatide in weight-loss trials, delivering 20.2% versus 23.6% weight reduction, triggering stock declines amid intensifying obesity drug competition.
LLYNVOclinical trialtirzepatide
BenzingaBenzinga··Vandana Singh

Novo Nordisk Shares Decline on CagriSema Trial Setback Versus Lilly Rival

Novo Nordisk shares plunged 13% after CagriSema obesity drug trial missed non-inferiority target versus Eli Lilly's tirzepatide, threatening competitive positioning.
LLYNVOFDA approvalclinical trial